COMING SOON
Frequently Asked Questions
COMING SOON
Browse through medical articles
Medical-on-the-Go: ATTD 2025
April 2025
Medical-on-the-Go is happy to share highlights from the recently concluded ATTD Congress 2025 Last March 19-22, 2025 in Amsterdam & online.
Medical-on-the-Go: The Soli-D RCT
September 2024
We would like to update you on a recently published randomized, head-to-head, open label phase 3 trial in Chinese people with Type 2 Diabetes Mellitus suboptimally controlled on OADs entitled the Soli-D study.
Medical-On-The-Go: Malik Study
June 2024
This real-world observational study by Malik et al. shows that initiation of iGlarLixi in people with T2D suboptimally controlled on OADs ± BI or GLP-1 RAs improves glycemic control with a low incidence of hypoglycaemia.
Browse through on-demand medical videos
COMING SOON
Listen through medical discussions
Medical-On-The-Go: Soli-D Podcast
In this episode, we delve into the Efficacy and safety of iGlarLixi versus IDegAsp in Chinese adults with type 2 diabetes, based on the findings from the Soli-D randomized controlled trial.
Medical-On-The-Go:Time in Range Podcast
In this episode, Dr Jeremy Pettus and Dr Steve Edelman discuss the increasing role of continuous glucose monitoring (CGM) and time-in-range (TIR) in diabetes management.
Browse through different medical cources
COMING SOON
Explore upcoming medical events
COMING SOON
Explore medical resources
COMING SOON
MAT-PH-2200980 | Version 1.0 | DA 04-2023 | DM 04-2023
For General Inquires – Contact us
If you experience any adverse event, i.e., anu unfavorable and unintended sign (an abnormal laboratory finding), symptom, or disease temporarily associated with the use of a medical product, please email it to PV.Philippines@sanofi.com
For Data Privacy requests and concerns:
Sanofi General Medicines (under sanofi-aventis Philippines, Inc.) and Sanofi Vaccines (under Sanofi Pasteur, Inc.): OneTrust
For General Inquires – Contact us
If you experience any adverse event, i.e., anu unfavorable and unintended sign (an abnormal laboratory finding), symptom, or disease temporarily associated with the use of a medical product, please email it to PV.Philippines@sanofi.com
For Data Privacy requests and concerns:
Sanofi General Medicines (under sanofi-aventis Philippines, Inc.) and Sanofi Vaccines (under Sanofi Pasteur, Inc.): OneTrust
For General Inquires – Contact us
If you experience any adverse event, i.e., anu unfavorable and unintended sign (an abnormal laboratory finding), symptom, or disease temporarily associated with the use of a medical product, please email it to PV.Philippines@sanofi.com
For Data Privacy requests and concerns:
Sanofi General Medicines (under sanofi-aventis Philippines, Inc.) and Sanofi Vaccines (under Sanofi Pasteur, Inc.): OneTrust